iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. iOnctura aims to improve current immune checkpoint therapies by developing novel drugs with potential best-in-class safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. Headquartered in Geneva, Switzerland, iOnctura was founded by M Ventures in June 2017.

Team Members
more about
Alicia Irurzun-Lafitte
more about
Hakan Goker
more about
Keno Gutierrez
Latest News Entry
iOnctura Announces Appointment of Leading International Scientific Advisory Board

iOnctura SA, a recently founded late stage preclinical immuno-oncology company, announced today the formation of an international Scientific Advisory Board (SAB).

M Ventures Creates New Immuno-Oncology Company iOnctura

Darmstadt, Germany, June 20, 2017 – Merck, a leading science and technology company, today announced its corporate venture arm M Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). CRT is the commercial arm of Cancer Research UK, London, UK. M Ventures will manage the investment and will be represented on iOnctura’s board of directors.

all portfolio news